“Some may look at recent failures and be discouraged,” wrote Richard Bedlack of the Duke ALS Clinic in Durham, North Carolina, in an e-mail to Alzforum. Thanks to advances in genetics and biomarkers, and a list of potential target pathways, “I think this is a time of unprecedented hope and excitement in ALS research”
CAMBRIDGE, Massachusetts, January 10, 2013 — The ALS Therapy Development Institute (ALS TDI) has entered into a new collaboration with to-BBB, a clinical stage biotechnology company focusing on enhanced drug delivery across the blood-brain barrier, to investigate potential treatments for ALS (aka Motor Neuron or Lou Gehrig’s disease).
“This partnership brings a new potential tool to [...]
The ALS Therapy Development Institute (ALS TDI) and the Gladstone Institutes today announced the formation of a research collaboration to speed the discovery of potential treatments for ALS through the preclinical drug development process.
The ALS Therapy Development Institute (ALS TDI) announced today that it has entered into collaboration with Neurotune to investigate a potential treatment for ALS (aka Motor Neuron or Lou Gehrig’s disease).
With regard to the development of an efficacious treatment for ALS, we are still in its infancy. There is much more to be done—and much more quickly than we’ve seen.
Many patients with Lou Gehrig’s disease, a fatal disorder formally known as amyotrophic lateral sclerosis, may want to try the drug on their own—even though there’s no evidence that it is safe or effective in patients with the disease.
The ALS Therapy Development Institute (ALS TDI) will launch a Phase II clinical trial on TDI 132 (aka:fingolimod/Gilenya®) as a potential treatment for ALS (Lou Gehrig’s disease).
“On one end of the spectrum you have people who are doing, essentially, badly designed uncontrolled human medical experiments for profit. And then at the other end of the spectrum you just have thieves who are preying on the sick and their families.”
A growing body of evidence suggests that malfunction of the immune system is at least part of the ALS disease process. Now scientists are testing whether mouse CTLA4-FC effectively blocks CD86
The following information was compiled from press sources including an article by Robert A. Goldstein posted December 29, 2011.
The nonprofit biotech, ALS Therapy Development Institute (ALS TDI) has formed a new partnership with Biogen Idec and UCB to further the development of compounds targeting the CD40 Ligand pathway in ALS. The terms of the agreement [...]